FDA Approves Hikma's Generic Vascepa Amid Fed. Circ. Fight

Law360 (May 22, 2020, 6:46 PM EDT) -- Hikma Pharmaceuticals on Friday announced that the U.S. Food and Drug Administration has approved its generic version of Amarin Pharma Inc.'s heart drug Vascepa, amid the companies' ongoing patent battle at the Federal Circuit.

The announcement comes a few months after a Nevada federal court ruled in favor of Hikma and held that Amarin's patents for the drug were invalid. The case is now on appeal at the Federal Circuit, which has sped up the briefing schedule.

"The approval for our generic version of Vascepa is an important milestone towards bringing this product to market," Brian Hoffmann, Hikma's president of generics,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!